Paul Hastings Advises Underwriters on Forte Biosciences’ Public Offering

Paul Hastings advised TD Cowen, Evercore ISI, Guggenheim Securities and Chardan as joint book-running managers, and Brookline Capital Markets, a division of Arcadia Securities, LLC, as co-manager, for Forte Biosciences, Inc.’s (Nasdaq: FBRX) public offering of 5,630,450 shares of its common stock and pre-funded warrants to purchase up to 619,606 shares of common stock. The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts,  commissions and other offering expenses. The offering is expected to close on or about June 26, 2025, subject to customary closing conditions.

Equity Capital Markets and Corporate Life Sciences chair Seo Salimi and partner Will Magioncalda led the Paul Hastings team.

More details can be found here.

About Paul Hastings

With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations. For more information, visit www.paulhastings.com.